Skip to main content
Fig. 5 | The Journal of Headache and Pain

Fig. 5

From: Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study

Fig. 5

Proportion of patients achieving ≥50% reduction in the monthly average number of migraine days over 6 months (mITT).a mITT, modified intent-to-treat; DB, double-blind; OLE, open-label extension. aAll patients in the OLE received fremanezumab 225 mg monthly

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us